In its second multibillion-dollar alliance, Voyager Therapeutics has entered into another collaboration and option agreement with AbbVie to research, develop and commercialise adeno-associated virus and other-virus-based gene therapies for the treatment of Parkinson’s disease and other synucleinopathies. In a deal value up to US$3.7 B, Voyager will perform research and preclinical work to vectorise antibodies directed against alpha-synuclein up to Phase I at its own expense at which point AbbVie has an option to license the resulting product for further clinical development.